Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|69|5|372-383

ISSN： 0030-2414

Source： Oncology, Vol.69, Iss.5, 2005-12, pp. : 372-383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 446-453

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

By  

Oncology, Vol. 60, Iss. 3, 2001-04 ,pp. : 214-220

Karger

Access to resources Recommend Favorite

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 3943-3951

John Wiley & Sons Inc

Access to resources Recommend Favorite

Feasibility and efficacy of dose‐dense and dose‐intense ABVD for high‐risk patients with advanced Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 662-665

John Wiley & Sons Inc

Access to resources Recommend Favorite